ArticleTranslational lung cancer research2026
Prognostic impact of CEACAM5 in nonsquamous non-small cell lung cancer: a critical reappraisal driven by cut-off optimization.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) has emerged as a promising therapeutic target for antibody-drug conjugates (ADCs) in nonsquamous non-small cell lung cancer (NSCLC). However, the landscape of CEACAM5 protein expression and its association with clinicopathological features in nonsquamous NSCLC remain poorly characterized. This study represents the first comprehensive investigation to profile CEACAM5 protein expression in this specific population using a clinical-grade immunohistochemistry (IHC) assay. Methods: We retrospectively analyzed 218 patients with resected nonsquamous NSCLC. A standardized IHC assay derived from a clinical trial was employed, utilizing a proprietary monoclonal antibody (clone 769) specifically developed for clinical application. We systematically evaluated the relationship between CEACAM5 expression and tumor characteristics using both a conventional therapeutic threshold (≥50%) and a sensitive data-driven cut-off (>0%) to explore the full spectrum of antigen expression. Results: The assay demonstrated excellent reproducibility. We found that CEACAM5 expression was significantly associated with markers of tumor aggressiveness, including lymphovascular and pleural invasion. Notably, the sensitive >0% cut-off revealed broader biological correlations than the restrictive ≥50% threshold. While CEACAM5 was not an independent prognostic factor in the overall cohort, a stage-specific, hypothesis-generating analysis-supported by external genomic validation-suggested that positive CEACAM5 expression may be associated with a trend towards poorer disease-free survival specifically in early-stage (stage I-II) patients, although this did not reach statistical significance (P=0.06). Conclusions: This study provides the first detailed characterization of CEACAM5 protein expression in nonsquamous NSCLC, establishing it as a biomarker linked to aggressive disease phenotypes. Our findings suggest that adopting a sensitive detection threshold (>0%) may better capture the population of patients with biologically active CEACAM5, thereby potentially refining candidate selection for targeted therapies and risk stratification in early-stage disease, a hypothesis that warrants prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.